Status:
COMPLETED
DIAgnostics for Multidrug Resistant Tuberculosis in Africa
Lead Sponsor:
Dissou AFFOLABI
Collaborating Sponsors:
Rwanda Biomedical Centre
The Tuberculosis Reference Laboratory Bamenda
Conditions:
Tuberculosis, Multidrug-Resistant
Eligibility:
All Genders
15+ years
Brief Summary
Recent advances in molecular diagnostics of tuberculosis, especially the GeneXpert Mycobacterium tuberculosis/Rifampicin test have reduced the time to diagnose Rifampicin Resistant Tuberculosis (RR-TB...
Detailed Description
The proposed DIAMA (DIAgnostics for Multidrug resistant tuberculosis in Africa) study aims to address current gaps in the diagnosis and management of patients with Multi-Drug-Resistant (MDR) tuberculo...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Being ≥ 15 year old
- Having a positive test on GeneXpert (M. tuberculosis) with or without resistance detected to rifampicin
- Willing and able to provide written informed consent, or for minors: assent from and consent from a legal representative
- Exclusion Criteria: None
Exclusion
Key Trial Info
Start Date :
May 4 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2022
Estimated Enrollment :
3356 Patients enrolled
Trial Details
Trial ID
NCT03303963
Start Date
May 4 2017
End Date
November 30 2022
Last Update
March 14 2023
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Tropical Medecine
Antwerp, Belgium
2
Centre National Hospitalier Universitaire de Pneumo-Phtisiologie de Cotonou
Cotonou, Atlantique/Littoral, Benin, 01BP321
3
The Tuberculosis Reference Laboratory Bamenda
Bamenda, Cameroon
4
Institut National de Recherche Biomédicale (INRB)
Kinshasa, Democratic Republic of the Congo